期刊文献+

TGF-β和P53在肾细胞癌中的表达及意义 被引量:3

Expression of TGF-beta and P53 in Renal Cell Carcinoma
下载PDF
导出
摘要 目的:通过检测转化生长因子-β(TGF-β)和P53在肾细胞癌(RCC)中的表达,探讨它们与肾癌的发生、病理分级、临床分期的关系。方法:免疫组织化学方法检测40例RCC石蜡标本中TGF-β和P53的蛋白表达,并分组进行统计学分析。结果:TGF-β与P53在RCC中表达率与对照组相比明显升高(P<0.05),但不同病理分级、临床分期之间差异无显著性(P>0.05)。TGF-β和P53表达存在正性相关,但两者在RCC中表达率存在显著性差异,TGF-β表达率高于P53的表达率(P<0.05)。结论:TGF-β和P53高表达可能成为肾癌的恶性表型之一,但两者与病理分级、临床分期无明显相关性。它们可能单独或协同作用调节细胞生长和转化,促进肾癌的发生。 Objective: To investigate the expression renal cell carcinoma(RCC). Methods: Protein of transforming growth factor-β(TGF-β)and P53 in expression of TGF-β and P53 in 40 RCC tissues was examined by immunohistochemical assay. Results: TGF-βand P53 showed an overexpression rate in RCC,but there were no significant differences among different pathological grades and clinical stages. A positive correlation was detected between TGF-β and P53, but the expression rate of TGF-β was higher than that of P53. Conclusion: Both the expression of TGF-β and P53 were malignant phenotypes in RCC,but there are no correlation at different pathological grades and clinical stages. Both may regulate cell growth and transformation for the occurrence of RCC solely or coooeratively.
出处 《武汉大学学报(医学版)》 CAS 2007年第5期584-587,I0002,共5页 Medical Journal of Wuhan University
基金 湖北省科技厅科技攻关项目(编号:2003AA301 D06)
关键词 肾细胞癌 转化生长因子-Β P53 免疫组化 Renal Cell Carcinoma Transforming Growth Factor-β P53 Immunohistochemistry
  • 相关文献

参考文献15

二级参考文献48

  • 1王大力,任重,张澍.喉癌组织中尿激酶型纤溶酶原激活剂及其抑制剂的表达及意义[J].肿瘤防治杂志,2005,12(11):829-832. 被引量:2
  • 2施承松,王祥珍.转化生长因子β_1在宫颈癌组织中的表达及其意义[J].广东医学院学报,2005,23(5):515-516. 被引量:3
  • 3张祥生,王子明,万恒麟.TGFβ抑制肿瘤细胞生长的作用及在泌尿系肿瘤中的研究现状[J].国外医学(泌尿系统分册),1996,16(1):17-19. 被引量:5
  • 4顾方六 吴阶平.肾肿瘤.泌尿外科学[M].济南:山东科学技术出版社,1993.476-492.
  • 5倪宗钻.医学统计学,第2版[M].北京:人民卫生出版社,1998.131-133.
  • 6[1]Robson CJ, Churchill BM, Auderson W. The results of radical nephrectomy for renal cell carcinoma[J]. J Urol,2002, 167 (2):873 - 875.
  • 7[2]Fuhrman SA. Prognosis significance of morphlogic parameters in renal carcinoma[J]. Am J Surg Pathol, 1982, 6 (7): 655 -663.
  • 8[3]Mai M, Qian C, Yokomizo A, et al. Loss of imprinting and allele Switching of p73 in renal cell carcinoma[ J ]. Oncogene, 1998,17(13): 1739 - 1741.
  • 9[4]Shiina H, Igawa M, Urakami S, et al. Clinical significance of immunohistochemically detectable p53 protein in renal cell carcinoma [J]. Eur Urol, 1999,31:73 -80.
  • 10[5]Kaghad M, Bonnet H, Yang A, et al. Monoallelically expressed gene related to p53 at 1 p36. A region frequently deleted in neuroblastoma and other human cancers[J]. Cell, 1997, 90 (4): 809-819.

共引文献22

同被引文献24

  • 1邱国战,周洪革,李旭东.p73和p53在肾癌中的表达及其意义[J].沈阳医学院学报,2004,6(2):68-70. 被引量:5
  • 2EBLE JN, SAUTER G, EPSTEIN JI, et al. World Health Organization classification of tumours. Pathology and genetics of tumors of the urinary system and male genital organs [M]. Lyon: IARC Press, 2004: 12-76.
  • 3ARGANI P, LAL P, HUTCHINSON B, et al. Aberrant nuclear immunoreactivity for TFE3 in neoplasms with TFE3 gene fusions: a sensitive and specific immunohistochemical assay [J]. Am J Surg Pathol, 2003, 27(6): 750-761.
  • 4KATERINA VG, JASON EH, OLGA VR, et al. p53 Pathway in Renal Cell Carcinoma ls Repressed by a Dominant Mechanism[J]. Cancer Research, 2004, 15(5): 1951-1958.
  • 5HIRATA H, HINODA Y, KIKUNO N, et al. MDM2 SNP309 ploymorphism as risk factor for susceptibility and poor prognosis in renal cell carcinoma[J]. Clin Cancer Res, 2007, 13(14): 4123-4129.
  • 6ARGANI P, ANTONESCU CR, ILLEI PB, et al. Primary renal neoplasms with the ASPL-TFE3 gene fusion of alveolar soft part sarcoma. Adistinetive tumor entity previously included among renal een carci- nomas of children and adoleseents [J]. Am J Pathol, 2001, 159: 179-192.
  • 7ARGANI P, ANTONESCU CR, COUTURIER J, et al. PRCC-TFE3 renal carcinomas. Morphologic, immunohistochemical, ultrastructural, and molecular analysis of an entity associated with the t (X;1)(p11.2; q21) [J]. Am J Surg Pathol, 2002, 26: 1553-1566.
  • 8HASHIMOTO H, SUE Y, SAGA Y, et al. Roles of p53 and MDM2 in tumor proliferation and determination of the prognosis of transitional cell carcinoma of the renal pelvis and ureter [J]. Int J Urol, 2000, 7(12): 457-463..
  • 9WARBURTON HE, BRADY M, VLATKOVI N, et al. P53 regulation and function in renal cell carcinoma[J]. Cancer Res, 2005, 65 (15): 6498-6503.
  • 10Dawn S,Richarda E,Lubna S,et al.TGF-βand P53 Staining in CT-Guided and Endoscopic Uhrasound Fine-Needle Aspirates of Pancreatic Adenocarcinoma[J].Digestive Diseases and Sciences,2004,49(5):828-832.

引证文献3

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部